 FOSTER CITY, Calif., Jan. 06, 2021 GLOBE NEWSWIRE -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data for VAX-A1, the Companys novel Group A Streptococcus Group A Strep conjugate vaccine candidate, in the journal Infectious Microbes Diseases. 